Area of research
Pulmonary and Respiratory Medicine · Pathology and Forensic Medicine
Research interest
Research interests include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Systemic Sclerosis and Related Diseases, Chronic Obstructive Pulmonary Disease (COPD) Research, and Sarcoidosis and Beryllium Toxicity Research.
Late-onset telomere biology disorders in adults: clinical insights and treatment outcomes from a retrospective registry cohort
Diagnosis and Treatment of Hypersensitivity Pneumonitis: S2k Guideline of the German Respiratory Society and the German Society for Allergology and Clinical Immunology
Image analysis: 68Ga-FAPI-46 PET derived texture parameters improve the differentiation of malignant and benign pulmonary lesions
Phase III FIBRONEER-IPF Trial of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis
ASPIRE Trial in Idiopathic Pulmonary Fibrosis: A Patient Experience-focused Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter Trial of the Novel Angiotensin II Type 2 Receptor Agonist Buloxibutid
Accelerate your career: the power of the ERS interstitial lung disease mentorship programme
The transcriptome of CD14+CD163-HLA-DRlow monocytes predicts mortality in Idiopathic Pulmonary Fibrosis
Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON)
The transcriptome of CD14 <sup>+</sup> CD163 <sup>−</sup> HLA-DR <sup>low</sup> monocytes predicts mortality in idiopathic pulmonary fibrosis
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial
Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial
Diagnostic Potential of Supplemental Static and Dynamic<sup>68</sup>Ga-FAPI-46 PET for Primary<sup>18</sup>F-FDG–Negative Pulmonary Lesions
Digital Smoking Cessation With a Comprehensive Guideline-Based App—Results of a Nationwide, Multicentric, Parallel, Randomized Controlled Trial in Germany
Design of ANCHOR-RA: a multi-national cross-sectional study on screening for interstitial lung disease in patients with rheumatoid arthritis
Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry
Therapie der Sarkoidose. Ein Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP)
Diagnostik und Therapie der exogen-allergischen Alveolitis
Worsening dyspnoea as a predictor of progression of pulmonary fibrosis
Is YouTube a sufficient source of information on Sarcoidosis?
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis (Update) and Progressive Pulmonary Fibroses: S2k Guideline of the German Respiratory Society
An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis
Development and initial validation of the ILD-Anxiety-Questionnaire (IAQ): A new instrument for assessing disease specific fears in interstitial lung disease
Pulmonary lymphangiomatosis: insights into an ultra-rare disease
The influence of the interventionalist's sex on the outcome and complications of transbronchial lung cryobiopsy
Modified blood cell GAP model as a prognostic biomarker in idiopathic pulmonary fibrosis
Pulmonary fibrosis: from pathogenesis to clinical decision-making
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis
S1-Leitlinie Interdisziplinäre Diagnostik interstitieller Lungenerkrankungen im Erwachsenenalter
Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)